OM · XBRL financial data

Outset Medical financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (OM's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025†Dec 31, 2025
Revenue from contracts with customers	50	103	115	130	114	119
Cost of goods and services sold	63	95	98	101	75	73
Gross profit	(13)	8	18	29	39	47
Research and development	29	37	49	57	38	21
General and administrative	31	36	41	45	43	38
Total operating expenses	104	138	179	199	152	113
Operating income (loss)	(117)	(131)	(161)	(170)	(113)	(67)
Interest expense	3	2	4	13	24	14
Income tax expense (benefit)	0	0	0	1	0	1
Net income (loss)	(121)	(132)	(163)	(173)	(128)	(82)
Earnings per share, basic USD per share	(4.85)	(2.89)	(3.38)	(3.48)	(2.46)	(5.37)
Earnings per share, diluted USD per share	(4.85)	(2.89)	(3.38)	(3.48)	(2.46)	(5.37)
Weighted average shares, basic millions of shares	0	0	0	0	0	0
Weighted average shares, diluted millions of shares	0	0	0	0	0	0

† Share count changed about 1/3 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (OM's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025†Dec 31, 2025
Cash and cash equivalents	295	182	73	69	124	35
Short-term investments	20	157	214	135	35	134
Marketable securities	—	—	155	65	3	—
Accounts receivable	6	26	28	33	36	28
Inventory	18	39	51	49	59	48
Prepaid and other current assets	6	6	7	6	5	6
Total current assets	346	410	374	291	258	251
Property and equipment, net	15	13	16	13	8	5
Right-of-use asset	8	7	6	5	4	5
Total assets	404	463	400	314	276	264
Accounts payable	5	2	1	6	4	1
Current portion of long-term debt	—	0	—	—	—	—
Total current liabilities	37	52	52	55	45	38
Long-term debt	30	30	96	130	197	96
Lease liability, non-current	8	7	6	4	3	3
Total liabilities	75	89	154	191	249	138
Accumulated deficit	(494)	(626)	(789)	(962)	(1,090)	(1,171)
Total stockholders' equity	329	374	246	123	27	127
Total liabilities and equity	404	463	400	314	276	264
Common shares outstanding (cover page) millions of shares	43	47	49	51	54	18

† Share count changed about 1/3 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (OM's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025†Dec 31, 2025
Net income (loss)	(121)	(132)	(163)	(173)	(128)	(82)
Stock-based compensation	21	17	27	39	29	16
Depreciation and amortization	3	5	5	6	6	4
Net cash from operating activities	(99)	(130)	(146)	(131)	(116)	(46)
Purchases of property and equipment	9	3	8	3	1	1
Net cash from investing activities	4	(143)	(66)	83	104	(98)
Proceeds from issuing common stock	255	149	0	0	—	—
Proceeds from long-term debt	30	0	96	33	67	98
Net cash from financing activities	386	160	73	44	68	56
Net change in cash	291	(113)	(139)	(5)	56	(89)

† Share count changed about 1/3 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 3845 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3845 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Outset Medical	35	32	(9.6)*	18.8M	15.3 quarters	Q2 FY26 10-QJun 30, 2026
ClearPoint Neuro	46	12	(20)	32.1M	6.6 quarters	Q3 FY26 10-QSep 30, 2026
EBR Systems	59	2.6	(17)*	75.3M	5.0 quarters	Q2 FY26 10-QJun 30, 2026
Orthopediatrics	17	73	4.5*	26.1M	—	Q3 FY26 10-QSep 30, 2026
NeuroPace	13	23	(3.9)*	34.3M	13.2 quarters	Q2 FY26 10-QJun 30, 2026
Butterfly Network	122	33	(2.3)*	not reported	10.3 quarters	Q3 FY26 10-QSep 30, 2026
Pulse Biosciences	102	0.4	(19)*	71.3M	5.4 quarters	Q2 FY26 10-QJun 30, 2026
SS Innovations International	14	not reported	(4.2)*	200.4M	3.2 quarters	Q2 FY26 10-QJun 30, 2026
Ceribell	42	29	(13)*	38.8M	7.8 quarters	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.